WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997037667) USE OF AN A1 ADENOSINE RECEPTOR AGONIST TO TREAT CEREBRAL ISCHAEMIA
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/037667    International Application No.:    PCT/US1997/005399
Publication Date: 16.10.1997 International Filing Date: 01.04.1997
Chapter 2 Demand Filed:    13.10.1997    
IPC:
A61K 31/70 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health, Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852 (US) (For All Designated States Except US).
VON LUBITZ, Dag, K., J., E. [US/US]; (US) (For US Only).
JACOBSON, Kenneth, A. [US/US]; (US) (For US Only)
Inventors: VON LUBITZ, Dag, K., J., E.; (US).
JACOBSON, Kenneth, A.; (US)
Agent: KILYK, John, Jr.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US)
Priority Data:
60/014,760 10.04.1996 US
60/019,073 09.05.1996 US
Title (EN) USE OF AN A1 ADENOSINE RECEPTOR AGONIST TO TREAT CEREBRAL ISCHAEMIA
(FR) EMPLOI D'UN AGONISTE DU RECEPTEUR DE L'ADENOSINE A1 POUR TRAITER UNE ISCHEMIE CEREBRALE
Abstract: front page image
(EN)The present invention provides a method of treating ischemic, hypoxic or anoxic brain damage in an animal comprising administering to an animal afflicted with ischemic, hypoxic, or anoxic brain damage, or an animal in imminent danger of suffering ischemic, hypoxic, or anoxic brain damage, a therapeutically effective amount of ADAC, or an analogue thereof.
(FR)Cette invention a trait à une technique thérapeutique de lésion cérébrale ischémique, hypoxique ou anoxique, chez un animal. Cette technique consiste à administrer, à l'animal souffrant de la lésion cérébrale susmentionnée ou à un animal risquant fort d'en souffrir, une quantité efficace, du point de vue thérapeutique, de N?6¿-[4 [[[ (2-aminoéthyl) amino]carbonyl]méthyl]phényl] adénosine (ADAC) ou d'un analogue de cette substance.
Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)